A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Atomoxetine (Strattera)

Norepinephrine Reuptake Inhibitor class · 8 generic manufacturers · 56 ANDAs filed at FDA.

First FDA approval2002-11-26
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$50.5M in CY2024 Part D spend514K claims · 122K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.406/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.414
Across all dosage forms in distribution.
Highest NADAC
$0.419
Range is tight.
Plans with PA
7 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Atomoxetine used for?

Atomoxetine is a Norepinephrine Reuptake Inhibitor medication tracked in Medicare Part D.

Is there a generic for Atomoxetine?

Yes. 56 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Atomoxetine?

Across 329 Part D plans, Atomoxetine averages $0.414/unit (NADAC). Lowest available: $0.406/unit. Highest in distribution: $0.419/unit.

Is Atomoxetine on the FDA shortage list?

No. Atomoxetine is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.